Tag - SILO

Developments

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

Silo Pharma (NASDAQ:SILO) has announced the initiation of a preclinical pharmacokinetic (PK) and tolerability study, in partnership with AmplifyBio, to assess Silo’s dissolvable, ketamine-based injectable implant, SP-26...

December 18, 2024

Developments

Silo partners with global CRO for preclinical study to advance homing peptide in MS

Silo Pharma (NASDAQ:SILO) has entered into an agreement with WuXi AppTec for a preclinical small animal study of SPU-16, a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS). Silo Pharma is...

August 7, 2024

Tag - SILO

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

Silo partners with global CRO for preclinical study to advance homing peptide in MS

General

More